Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2024-04-08 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of March 31, 2024. This type of periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital structure changes or mandatory disclosures. It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA). Since it deals directly with the composition of the share capital and voting rights, it aligns best with 'Share Issue/Capital Change' (SHA) or potentially a specific regulatory filing (RNS). Given the focus on the total number of shares and voting rights, SHA is the most precise fit, as it relates directly to the capital structure components being reported monthly.
2024-04-08 French
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant business event: Ipsen and Sutro Biopharma signing an exclusive worldwide license agreement for a drug candidate (STRO-003). It details the terms of the deal, financial considerations, and includes standard sections like 'À propos de...' (About Us) and 'Avertissements et/ou déclarations prospectives' (Forward-looking statements). This format is characteristic of a corporate announcement intended for immediate public dissemination, often preceding a formal regulatory filing or serving as the primary public disclosure for a material event. Since it is a press release announcing a major transaction/partnership rather than a formal periodic report (10-K, IR), a dividend notice (DIV), or a specific regulatory filing like insider trading (DIRS), it best fits the general category for corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially an announcement about a transaction (TAR, though this is more about M&A activity, and this is a licensing deal). Given the context of a press release announcing a major licensing deal and partnership, and lacking specific keywords for the other categories, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for a press release of this nature, although it is a very specific type of announcement. However, since it is a press release announcing a major business development (licensing agreement), it is not a standard financial report (10-K, IR, ER). It is not a proxy statement (PSI) or AGM material (AGM-R). It is a general corporate announcement. RNS serves as the best fallback for non-standard, material announcements. If 'TAR' (M&A Activity) were interpreted broadly to include significant licensing deals, that could be considered, but RNS is safer for a general press release format.
2024-04-02 French
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
M&A Activity Classification · 1% confidence The document is a press release dated April 2, 2024, announcing an exclusive global licensing agreement between Ipsen and Sutro Biopharma regarding an Antibody-Drug Conjugate (ADC) called STRO-003. This type of announcement details a significant business transaction, specifically related to drug development rights and potential future payments/milestones. This fits best under 'Capital/Financing Update' (CAP) as it involves a major financial/licensing deal, or potentially 'Regulatory Filings' (RNS) if it were a generic disclosure, but the specific nature points towards a transaction update. Since there is no specific category for 'Licensing Agreement' or 'M&A Activity' (TAR is for M&A/Takeover Bids), and it is a major corporate transaction involving significant financial terms (\$900m potential), 'CAP' (Capital/Financing Update) is the most appropriate fit among the provided options, as licensing deals often fall under financing/corporate transaction disclosures. It is not an ER, IR, 10-K, or CT.
2024-04-02 English
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' in accordance with French regulatory articles (AMF). It presents a table showing the total number of shares and the total number of voting rights as of a specific date (February 29, 2024). This type of regular disclosure regarding the capital structure and voting power is a specific regulatory filing requirement, but it does not fit perfectly into the defined categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning share capital and voting rights. Since it is a specific, recurring regulatory disclosure that isn't covered by the more specific codes (like DVA for voting *results* or SHA for *issuance*), the most appropriate general regulatory fallback is RNS (Regulatory Filings), as it is a mandatory disclosure to the market regarding capital structure.
2024-03-07 English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of February 29, 2024. This content directly relates to changes in the capital structure, specifically the total number of shares and associated voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA). It is a formal regulatory disclosure regarding the capital base.
2024-03-07 French
Ipsen S.A. publie ses comptes consolidés 2023
Audit Report / Information Classification · 1% confidence The document is titled "COMPTE CONSOLIDÉS 2023" (Consolidated Accounts 2023) and contains a detailed table of contents listing sections like 'Compte de résultat consolidé' (Consolidated Income Statement), 'Bilan consolidé' (Consolidated Balance Sheet), 'Tableau des flux de trésorerie consolidés' (Consolidated Cash Flow Statement), and numerous detailed financial notes (Note 1 through Note 26). The content explicitly shows comparative financial figures for 2023 and 2022, including revenue, operating result, and net result. This structure and content are characteristic of a comprehensive annual financial report, which corresponds to the definition of a 10-K (Annual Report), even though the document is in French and likely filed under a local equivalent (like a 'Document d'Enregistrement Universel' or similar annual filing). Given the options, '10-K' is the closest classification for a full annual financial report. FY 2023
2024-02-15 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.